Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer

Background: Trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) are HER2-targeting antibody-drug conjugates (ADCs) with activity in HER2-mutant non-small cell lung cancer (NSCLC). Whether patients benefit from sequential HER2-directed ADCs therapy remains unknown. Methods: We conducted...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Daniel Reinhorn, MD, Jonathan Kuten, MD, MHA, Isabel Preeshagul, DO, MBS, Juliana Eng, MD, Kenneth Ng, MD, Alexander Drilon, MD, Jamie Chaft, MD, Fernando C. Santini, MD, Mark M. Awad, MD, PhD
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2026-07-01
Цуврал:	JTO Clinical and Research Reports
Нөхцлүүд:	Non-small cell lung cancer ERBB2 mutation Antibody-drug conjugate Trastuzumab deruxtecan Trastuzumab emtansine Treatment sequencing
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2666364326000755
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!